Displaying drugs 6676 - 6700 of 8039 in total
Nefiracetam
Nefiracetam has been used in trials studying the treatment of Alzheimer's Disease.
Investigational
Matched Description: … Nefiracetam has been used in trials studying the treatment of Alzheimer's Disease. …
Ketodarolutamide
Ketodarolutamide, a nonsteroidal antiandrogen (NSAA), is the major active metabolite of darolutamide.
Experimental
Matched Description: … Ketodarolutamide, a nonsteroidal antiandrogen (NSAA), is the major active metabolite of [darolutamide …
GSBR-1290
GSBR-1290 is a small molecule agonist of the GLP-1 receptor.
Investigational
Matched Description: … GSBR-1290 is a small molecule agonist of the GLP-1 receptor. …
SGN-30
SGN-30 is an engineered monoclonal antibody (mAb) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a variety of hematologic malignancies as compared to on normal cells. SGN-30 has been shown to induce direct anti-cancer activity towards tumor cells expressing CD30 and is undergoing phase...
Investigational
Matched Description: … ) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a variety of ... with chemotherapy for the treatment of relapsed Hodgkin lymphoma, front-line ALCL and pediatric ALCL ... We are collaborating with the National Cancer Institute (NCI) on three clinical trials of SGN-30 in combination …
ATL1102
ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.
Investigational
Matched Description: … ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, …
Laromustine
VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.
Investigational
Matched Description: … VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia …
Tandamine
Tandamine was researched in 1970s as an antidepressant but was never commercialized. Tandamine is an analog of pirandamine and it acts as a selective serotonin reuptake inhibitor (SSRI).
Experimental
Matched Description: … Tandamine is an analog of pirandamine and it acts as a selective serotonin reuptake inhibitor (SSRI). …
Eleclazine
Eleclazine has been used in trials studying the treatment of LQT2 Syndrome, Long QT Syndrome, Ischemic Heart Disease, Ventricular Arrhythmia, and Long QT Syndrome Type 3, among others.
Investigational
Matched Description: … Eleclazine has been used in trials studying the treatment of LQT2 Syndrome, Long QT Syndrome, Ischemic …
MIP-1095 I-123
123 I Mip 1095 is under investigation in clinical trial NCT00712829 (Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents).
Investigational
Matched Description: … NCT00712829 (Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of …
Nerofe
Nerofe is under investigation in clinical trial NCT03059615 (A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS).
Investigational
Matched Description: … Nerofe is under investigation in clinical trial NCT03059615 (A Phase 2a, Open-Label, Two Stage Study of …
Tavapadon
Tavapadon is under investigation in clinical trial NCT02262767 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects).
Investigational
Matched Description: … in clinical trial NCT02262767 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of …
PCS-499
PCS-499 is under investigation in clinical trial NCT01487109 (A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients).
Investigational
Matched Description: … under investigation in clinical trial NCT01487109 (A Phase 2 Study to Evaluate the Safety and Efficacy of …
Ontamalimab
Ontamalimab is under investigation in clinical trial NCT03627091 (Efficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)).
Investigational
Matched Description: … Ontamalimab is under investigation in clinical trial NCT03627091 (Efficacy and Safety Study of SHP647 …
Silmitasertib
Silmitasertib is under investigation in clinical trial NCT03904862 (Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery).
Investigational
Matched Description: … Silmitasertib is under investigation in clinical trial NCT03904862 (Testing the Safety and Tolerability of …
Zampilimab
Zampilimab is under investigation in clinical trial NCT04335578 (A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of UCB7858 in Adult Kidney Transplant Recipients With Chronic Allograft Injury).
Investigational
Matched Description: … clinical trial NCT04335578 (A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of …
Volagidemab
Volagidemab is under investigation in clinical trial NCT03117998 (Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus).
Investigational
Matched Description: … clinical trial NCT03117998 (Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of …
MaxAdFVIII
MaxAdFVIII is an adenoviral vector that expresses the full-length human Factor VIII (hFVIII) cDNA. First developed by GenStar, it is being investigated for the treatment of hemophilia.
Investigational
Matched Description: … First developed by GenStar, it is being investigated for the treatment of hemophilia. …
RLYB212
RLYB212 is a human monoclonal antibody against Antigen-1A Immunoglobulin (HPA-1A). It is currently being developed by Rallybio for the prevention of fetal and neonatal alloimmune thrombocytopenia.
Investigational
Matched Description: … It is currently being developed by Rallybio for the prevention of fetal and neonatal alloimmune thrombocytopenia …
Bacteroides thetaiotaomicron
Bacteroides thetaiotaomicron is a live biotherapeutic. Developed by 4D Pharma, Thetanix, an oral formulation comprising lyophilized Bacteroides thetaiotaomicron, is being investigated for the treatment of Crohn’s disease.
Investigational
Matched Description: … formulation comprising lyophilized Bacteroides thetaiotaomicron, is being investigated for the treatment of …
Ispectamab debotansine
Ispectamab debotansine is an antibody drug conjugate comprised of an anti-B cell maturation (BCMA) IgG1 humanized antibody conjugated covalently to the dibenzocyclooctyne (DBCO) noncleavable linker maytansinoid warhead.
Investigational
Matched Description: … Ispectamab debotansine is an antibody drug conjugate comprised of an anti-B cell maturation (BCMA) IgG1 …
LMB-100
LMB-100 is a is an antibody-toxin conjugate with an antimesothelin Fab linked to a 24-kilodalton portion of Pseudomonas exotoxin A with mutations that decrease immunogenicity.
Investigational
Matched Description: … 100 is a is an antibody-toxin conjugate with an antimesothelin Fab linked to a 24-kilodalton portion of …
Sitamaquine
Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of visceral leishmaniasis.
Investigational
Matched Description: … Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of …
GI-4000
A vaccine containing a heat-killed recombinant Saccharomyces cerevisiae yeast transfected with mutated forms of Ras, an oncogene frequently found in solid tumors, with potential immunostimulant and antitumor activity.
Investigational
Matched Description: … containing a heat-killed recombinant Saccharomyces cerevisiae yeast transfected with mutated forms of …
EGEN-001
EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity.
Investigational
Matched Description: … EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin …
BMS-564929
BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
Experimental
Matched Description: … So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause. …
Displaying drugs 6676 - 6700 of 8039 in total